Claudio E Chuaqui

7691865, Apr 6, 2010

Sep 5, 2003

10/526839

Mary Beth Carter - Arlington MA, US
Lihong Sun - Arlington MA, US
Paul Lyne - Arlington MA, US
Claudio Chuaqui - Somerville MA, US
Zhongli Zheng - Lexington MA, US
Juswinder Singh - Ashland MA, US

Biogen Idec MA Inc. - Cambridge MA

A61K 31/519
C07D 471/02
C07D 487/04

5142593, 514303, 544281, 546117

Compounds of formula I possess unexpectedly high affinity for Alk 5 and/or Alk 4, and can be useful as antagonists thereof for preventing and/or treating numerous diseases, including fibrotic disorders. In one embodiment, the invention features a compound of formula I:.

20060063809, Mar 23, 2006

Apr 4, 2003

10/510459

Lihong Sun - Arlington MA, US
Feng Shan - Burlington MA, US
Claudio Chuaqui - Somerville MA, US
Zhongli Zheng - Lexington MA, US
Russell Petter - Stow MA, US

A61K 31/4545
A61K 31/4439
C07D 403/14

514318000, 514341000, 546193000, 546272700

Compounds of formula (I) possess unexpectedly high affinity for Alk 5 and/or Alk 4, and can be useful as antagonists thereof for preventing and/or treating numerous diseases, including fibrotic disorders. In one embodiment, the invention features a compound of the general formula (I).

20060135517, Jun 22, 2006

Sep 5, 2003

10/526653

Mary Carter - Arlington MA, US
Lihong Sun - Arlington MA, US
Claudio Chuaqui - Somerville MA, US
Juswinder Singh - Ashland MA, US
Michael Choi - Cambridge MA, US

A61K 31/5377
C07D 471/02
A61K 31/506

514234500, 514303000, 514275000, 544127000, 544331000

Compounds of formula I possess unexpectedly high affinity for Alk 5 and/or Alk 4, and can be useful as antagonists thereof for preventing and/or treating numerous diseases, including fibrotic disorders. In one embodiment, the invention features a compound of formula I:

20060264440, Nov 23, 2006

Feb 12, 2004

10/545179

Lihong Sun - Arlington MA, US
Feng Shan - Braintree MA, US
Claudio Chuaqui - Somerville MA, US
Mark Cornebise - Watertown MA, US
Timothy Pontz - Brighton MA, US
Mary Carter - Arlington MA, US
Juswinder Singh - Ashland MA, US
Leona Ling - Winchester MA, US
Russell Petter - Stow MA, US

BIOGEN IDEC MA INC. - Cambridge MA

A61K 31/522
A61K 31/52
A61K 31/519
A61K 31/517
C07D 473/02
C07D 487/04

514249000, 544238000, 544235000, 544281000, 544284000, 544353000, 544277000, 544278000, 514252020, 514252040, 514263200, 514260100, 514259100, 514266200, 514266210

The invention is based on the discovery that compounds of formula I possess unexpectedly high affinity for Alk 5 and/or Alk 4, and can be useful as antagonists thereof for preventing and/or treating numerous diseases, including fibrotic disorders. In one embodiment, the invention features a compound of formula I (I).

20070020642, Jan 25, 2007

Aug 18, 2005

11/206034

Zhan Deng - Markham, CA
Claudio Chuaqui - Somerville MA, US
Juswinder Singh - Ashland MA, US

C12Q 1/68
G06F 19/00

435006000, 702019000, 702020000

Disclosed is a method for representing and analyzing 3D target molecule-ligand intermolecular interactions. The method generates structural interaction fingerprints (SIFts) that convert three-dimensional structural interaction information into linear information strings that contains a plurality of information blocks; each of which in turn containing a plurality of information units. By assigning to each information unit a calculated value to represent the characteristic of a set of intermolecular interactions occurring at each selected position (i.e., a position on the target molecule at which intermolecular interaction occurs), a SIFt of the target molecule-ligand complex is constructed.

20070134662, Jun 14, 2007

Jul 1, 2004

10/562974

Juswinder Singh - Ashland MA, US
Claudio Chuaqui - Arlington MA, US
Zhan Deng - Winchester MA, US

C12Q 1/68
G01N 33/53
G06F 19/00

435006000, 435007100, 702020000

Disclosed is a method for representing and analyzing 3D target molecule-ligand intermolecular interactions. The method generates structural interaction fingerprints (SIFts) that convert three-dimensional structural interaction information into linear information strings that contains a plurality of information blocks; each of which in turn containing a plurality of information units. By assigning to each information unit a calculated value to represent the characteristic of a set of intermolecular interactions occurring at each selected position (i.e., a position on the target molecule at which intermolecular interaction occurs), a SIFt of the target molecule-ligand complex is constructed.

20080171755, Jul 17, 2008

Aug 24, 2005

11/661531

Lihong Sun - Arlington MA, US
Claudio Chuaqui - Somerville MA, US
Juswinder Singh - Ashand MA, US
Feng Shan - Braintree MA, US

A61K 31/506
C07D 405/14
C12N 5/06
A61P 35/00
A61P 35/02
A61P 25/28

514256, 544333, 435375

The invention is based on the discovery that compounds of formula (I) possess high affinity for Alk 5 and/or Alk 4, and can be useful as antagonists thereof for preventing and/or treating numerous diseases, including fibrotic disorders. The invention features a compound of formula (I) and uses thereof: formula (I).

20100056505, Mar 4, 2010

Nov 21, 2006

12/085380

Mary Beth Carter - Lawrence KS, US
Claudio Chuaqui - Arlington MA, US
Kevin Guckian - Marlborough MA, US
Edward Lin - Chesnut Hill MA, US
Michael J. Choi - San Diego CA, US
Zhan Deng - Winchester MA, US
Lihong Sun - Lexington MA, US

A61K 31/498
C07D 403/02
C07D 401/14
C07D 409/14
C07D 403/12
C07D 417/14
C07D 413/14
A61K 31/541
A61K 31/5377
A61P 43/00
A61P 35/00
A61P 9/00
A61P 9/12

5142282, 544353, 544 581, 544116, 514249, 5142348

The invention is related to compounds of formula (I) as antagonists of the TGFβ family type I receptors, Alk5 and/or AIk 4, compositions and methods of use. The compounds of formula (I) can be employed in the prevention and/or treatment of diseases such as fibrosis (e.g., renal fibrosis, pulmonary fibrosis, and hepatic fibrosis), progressive cancers, or other diseases for which reduction of TGFβ family signaling activity is desirable.